RECOMBINANT IL-1B IN THE COMBINATION THERAPY OF CHRONIC HEPATITIS C
The article highlights the problems of current antiviral therapy for chronic hepatitis C (CHC). The efficacy of combination therapy with pegylated interferon and ribavirin in patients infected with virus genotype l is not more than 50%. Incorporation of the hepatitis C virus protease inhibitors telaprevir and boceprevir increases sustained virological response in primary patients with CHC genotype l, but this therapy is expensive and accompanied by more serious complications. Because of its high cost, the therapy is inaccessible to a large group of patients in the Russian Federation. The given paper analyzes the results of clinical trials of the Russian recombinant IL-1β in the combined antiviral therapy of CHC.